Lannett Co Company Profile (NYSE:LCI)

About Lannett Co (NYSE:LCI)

Lannett Co logoLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LCI
  • CUSIP: 51601210
  • Web:
  • Market Cap: $863.12 million
  • Outstanding Shares: 37,284,000
Average Prices:
  • 50 Day Moving Avg: $18.58
  • 200 Day Moving Avg: $20.17
  • 52 Week Range: $14.90 - $27.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 8.42
  • P/E Growth: -0.83
Sales & Book Value:
  • Annual Revenue: $637.34 million
  • Price / Sales: 1.35
  • Book Value: $15.20 per share
  • Price / Book: 1.52
  • EBITDA: $245 million
  • Net Margins: -0.09%
  • Return on Equity: 19.80%
  • Return on Assets: 6.42%
  • Debt-to-Equity Ratio: 1.50%
  • Current Ratio: 2.72%
  • Quick Ratio: 2.09%
  • Average Volume: 718,748 shs.
  • Beta: 2.76
  • Short Ratio: 26.43

Frequently Asked Questions for Lannett Co (NYSE:LCI)

What is Lannett Co's stock symbol?

Lannett Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett Co's earnings last quarter?

Lannett Co Inc (NYSE:LCI) issued its earnings results on Wednesday, August, 23rd. The company reported $0.40 EPS for the quarter, hitting the Zacks' consensus estimate of $0.40. The business had revenue of $139.10 million for the quarter, compared to analyst estimates of $139.01 million. Lannett Co had a negative net margin of 0.09% and a positive return on equity of 19.80%. The company's quarterly revenue was down 17.6% compared to the same quarter last year. During the same period last year, the company posted $0.73 earnings per share. View Lannett Co's Earnings History.

When will Lannett Co make its next earnings announcement?

Lannett Co is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Lannett Co.

Where is Lannett Co's stock going? Where will Lannett Co's stock price be in 2017?

5 equities research analysts have issued 12 month target prices for Lannett Co's shares. Their predictions range from $18.00 to $27.00. On average, they expect Lannett Co's share price to reach $21.00 in the next twelve months. View Analyst Ratings for Lannett Co.

Who are some of Lannett Co's key competitors?

Who are Lannett Co's key executives?

Lannett Co's management team includes the folowing people:

  • Jeffrey Farber, Chairman of the Board
  • Arthur P. Bedrosian J.D., Chief Executive Officer, Director
  • Martin P. Galvan CPA, Chief Financial Officer, Vice President - Finance, Treasurer
  • Robert Ehlinger, Vice President - Logistics, Chief Information Officer
  • Samuel H. Israel, Vice President, General Counsel, Chief Legal Officer
  • Kevin R. Smith, Vice President - Sales and Marketing
  • John M. Abt, Vice President - Quality
  • David Drabik, Lead Independent Director
  • Patrick G. LePore, Independent Director
  • James M. Maher, Independent Director

How do I buy Lannett Co stock?

Shares of Lannett Co can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett Co's stock price today?

One share of Lannett Co stock can currently be purchased for approximately $23.15.

MarketBeat Community Rating for Lannett Co (NYSE LCI)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about Lannett Co and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lannett Co (NYSE:LCI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $21.00 (9.29% downside)
Consensus Price Target History for Lannett Co (NYSE:LCI)
Price Target History for Lannett Co (NYSE:LCI)
Analysts' Ratings History for Lannett Co (NYSE:LCI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2017BMO Capital MarketsReiterated RatingMarket Perform$26.00 -> $20.00HighView Rating Details
8/23/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
8/22/2017Roth CapitalSet Price TargetBuy$27.00HighView Rating Details
8/14/2017Deutsche Bank AGLower Price TargetHold$23.00 -> $19.00MediumView Rating Details
5/3/2017Robert W. BairdReiterated RatingOutperform$18.00MediumView Rating Details
8/24/2016Raymond James Financial, Inc.Boost Price TargetOutperform$31.00 -> $43.00N/AView Rating Details
3/25/2016Susquehanna Bancshares IncLower Price Target$37.00 -> $30.00N/AView Rating Details
3/25/2016Craig HallumLower Price TargetBuy$35.00N/AView Rating Details
3/24/2016Canaccord GenuityDowngradeBuy -> Sell$28.00 -> $18.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Lannett Co (NYSE:LCI)
Earnings by Quarter for Lannett Co (NYSE:LCI)
Earnings History by Quarter for Lannett Co (NYSE LCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/23/2017Q4 2017$0.40$0.40$139.01 million$139.10 millionViewN/AView Earnings Details
5/2/2017Q3 2017$0.87$0.77$170.28 million$165.72 millionViewListenView Earnings Details
2/1/2017Q217$0.84$0.92$169.04 million$171.00 millionViewListenView Earnings Details
11/3/2016Q117$0.71$0.77$166.72 million$161.60 millionViewN/AView Earnings Details
8/23/2016Q416$0.59$0.73$161.55 million$168.90 millionViewListenView Earnings Details
5/3/2016Q316$0.63$0.75$160.49 million$163.70 millionViewN/AView Earnings Details
2/3/2016Q216$0.94$0.95$141.62 million$127.06 millionViewN/AView Earnings Details
11/4/2015Q116$0.89$0.99$103.90 million$106.40 millionViewN/AView Earnings Details
8/25/2015Q415$0.86$0.91$97.21 million$99.28 millionViewListenView Earnings Details
5/6/2015Q315$0.94$0.97$101.10 million$99.40 millionViewN/AView Earnings Details
2/4/2015Q215$1.06$1.21$102.95 million$114.80 millionViewN/AView Earnings Details
11/3/2014Q115$0.79$0.94$91.40 million$93.40 millionViewN/AView Earnings Details
8/27/2014Q414$0.63$0.64$79.50 million$80.60 millionViewN/AView Earnings Details
5/7/2014Q314$0.60$0.63$84.50 million$80.00 millionViewN/AView Earnings Details
2/6/2014Q214$0.39$0.46$62.21 million$67.30 millionViewN/AView Earnings Details
11/7/2013Q114$0.13$0.22$41.14 million$45.82 millionViewN/AView Earnings Details
9/10/2013Q4 2013$0.07$0.12$37.89 million$40.20 millionViewN/AView Earnings Details
5/8/2013Q3 2013$0.13$0.14$35.14 million$39.00 millionViewN/AView Earnings Details
2/7/2013Q2 2013$0.05$0.10$33.53 million$36.60 millionViewN/AView Earnings Details
11/8/2012Q113$0.05$0.07$33.76 million$35.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Lannett Co (NYSE:LCI)
2017 EPS Consensus Estimate: $3.28
2018 EPS Consensus Estimate: $2.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.65$0.73$0.69
Q2 20173$0.80$0.91$0.86
Q3 20173$0.82$0.93$0.89
Q4 20173$0.72$0.93$0.84
Q1 20182$0.52$0.68$0.60
Q2 20182$0.68$0.76$0.72
Q3 20182$0.72$0.80$0.76
Q4 20182$0.73$0.90$0.82
(Data provided by Zacks Investment Research)


Dividend History for Lannett Co (NYSE:LCI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Lannett Co (NYSE:LCI)
Insider Ownership Percentage: 15.04%
Institutional Ownership Percentage: 87.92%
Insider Trades by Quarter for Lannett Co (NYSE:LCI)
Institutional Ownership by Quarter for Lannett Co (NYSE:LCI)
Insider Trades by Quarter for Lannett Co (NYSE:LCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Arthur P BedrosianCEOBuy10,000$20.00$200,000.00View SEC Filing  
12/2/2016David FarberMajor ShareholderSell3,800$25.00$95,000.00View SEC Filing  
9/15/2016G. Michael LandisInsiderSell4,334$32.30$139,988.20View SEC Filing  
9/1/2016James M MaherDirectorSell1,478$33.91$50,118.98View SEC Filing  
8/31/2016G. Michael LandisInsiderSell6,786$33.41$226,720.26View SEC Filing  
6/23/2016Robert EhlingerVPSell37,141$25.06$930,753.46View SEC Filing  
6/20/2016Robert EhlingerVPSell62,859$25.40$1,596,618.60View SEC Filing  
3/1/2016Robert EhlingerVPSell69,247$25.41$1,759,566.27View SEC Filing  
2/5/2016Arthur P BedrosianCEOBuy4,500$24.91$112,095.00View SEC Filing  
2/5/2016David A DrabikDirectorBuy1,277$24.74$31,592.98View SEC Filing  
2/5/2016Kevin SmithVPBuy1,500$24.75$37,125.00View SEC Filing  
2/5/2016Martin P GalvanCFOBuy3,000$24.65$73,950.00View SEC Filing  
9/15/2015Arthur P BedrosianCEOSell5,000$55.64$278,200.00View SEC Filing  
9/8/2015John AbtVPBuy1,000$54.77$54,770.00View SEC Filing  
8/17/2015Arthur P BedrosianCEOSell5,000$52.81$264,050.00View SEC Filing  
7/15/2015Arthur P BedrosianCEOSell5,000$61.92$309,600.00View SEC Filing  
6/15/2015Arthur P BedrosianCEOSell5,000$56.31$281,550.00View SEC Filing  
5/15/2015Arthur P BedrosianCEOSell5,000$53.27$266,350.00View SEC Filing  
4/15/2015Arthur P BedrosianCEOSell5,000$69.43$347,150.00View SEC Filing  
3/16/2015Arthur P BedrosianCEOSell5,000$65.23$326,150.00View SEC Filing  
3/16/2015William SchreckCOOSell134,635$64.99$8,749,928.65View SEC Filing  
3/6/2015William SchreckCOOSell50,000$63.35$3,167,500.00View SEC Filing  
2/18/2015David A DrabikDirectorSell12,500$61.55$769,375.00View SEC Filing  
2/17/2015Arthur P BedrosianCEOSell5,000$59.89$299,450.00View SEC Filing  
2/17/2015G. Michael LandisInsiderSell11,500$58.60$673,900.00View SEC Filing  
2/13/2015Jeffrey FarberDirectorSell35,000$58.18$2,036,300.00View SEC Filing  
2/11/2015Kevin SmithVPSell109,436$56.51$6,184,228.36View SEC Filing  
2/9/2015David FarberMajor ShareholderSell2,500$55.00$137,500.00View SEC Filing  
2/9/2015Kevin SmithVPSell53,534$55.36$2,963,642.24View SEC Filing  
2/6/2015G. Michael LandisInsiderSell12,049$52.93$637,753.57View SEC Filing  
1/26/2015David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
1/15/2015Arthur P BedrosianCEOSell5,000$43.50$217,500.00View SEC Filing  
12/15/2014Arthur P BedrosianCEOSell5,000$43.81$219,050.00View SEC Filing  
12/10/2014Martin P GalvanCFOBuy1,000$42.40$42,400.00View SEC Filing  
12/8/2014Ernest SaboVPSell6,000$48.03$288,180.00View SEC Filing  
10/27/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
9/16/2014Arthur P BedrosianCEOSell5,000$40.05$200,250.00View SEC Filing  
8/18/2014David FarberMajor ShareholderSell5,000$41.30$206,500.00View SEC Filing  
7/15/2014Arthur P BedrosianCEOSell5,000$47.19$235,950.00View SEC Filing  
6/23/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
6/16/2014Arthur P BedrosianCEOSell5,000$46.96$234,800.00View SEC Filing  
6/16/2014David FarberMajor ShareholderSell10,000$43.53$435,300.00View SEC Filing  
6/16/2014Paul TaveiraDirectorSell1,000$46.94$46,940.00View SEC Filing  
3/17/2014William SchreckCOOSell16,600$43.85$727,910.00View SEC Filing  
3/12/2014William SchreckCOOSell55,563$43.31$2,406,433.53View SEC Filing  
2/20/2014Kevin SmithVPSell64,665$45.11$2,917,038.15View SEC Filing  
2/13/2014Kevin SmithVPSell20,000$40.48$809,600.00View SEC Filing  
12/13/2013Arthur BedrosianCEOBuy5,000$27.85$139,250.00View SEC Filing  
12/13/2013Martin GalvanCFOBuy3,000$26.90$80,700.00View SEC Filing  
5/14/2013Kevin SmithVPSell24,984$11.86$296,310.24View SEC Filing  
5/13/2013Kevin SmithVPSell41,929$11.80$494,762.20View SEC Filing  
5/10/2013Ernest SaboVPSell15,000$11.29$169,350.00View SEC Filing  
3/14/2013Paul TaveiraDirectorBuy1,000$9.73$9,730.00View SEC Filing  
2/13/2013Martin P GalvanCFOBuy4,000$6.88$27,520.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Lannett Co (NYSE:LCI)
Latest Headlines for Lannett Co (NYSE:LCI)
DateHeadline logoCritical Contrast: Lannett Co (LCI) & The Competition - October 15 at 4:28 AM logo Brokerages Anticipate Lannett Co Inc (LCI) Will Announce Quarterly Sales of $153.21 Million - October 13 at 3:04 AM logoFY2018 EPS Estimates for Lannett Co Inc (LCI) Raised by Oppenheimer Holdings - October 12 at 1:54 PM logoLannett Co Inc (LCI) Expected to Post Earnings of $0.52 Per Share - October 11 at 8:36 PM logoLannett Co Inc Expected to Earn Q1 2018 Earnings of $0.52 Per Share (LCI) - October 11 at 10:12 AM logoFinancial Contrast: Lannett Co (LCI) and Its Competitors - October 10 at 9:06 AM logoETFs with exposure to Lannett Co., Inc. : October 9, 2017 - October 9 at 4:25 PM logoImpax Laboratories (IPXL) vs. Lannett Co (LCI) Financial Survey - October 9 at 4:12 PM logoLannett Co Inc (LCI) Receives Average Rating of "Hold" from Brokerages - October 7 at 6:50 PM logoLannett Co., Inc. :LCI-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017 - October 7 at 2:21 AM logoLannett (LCI) Shares Cross Above 200 DMA - October 2 at 4:57 PM logoLannett Company Inc (LCI): What Does It Mean For Your Portfolio? - October 2 at 4:57 PM logoFDA OKs Lannett's generic Prevacid; shares ahead 8% - October 2 at 12:31 PM logoLannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : September 28, 2017 - October 2 at 12:30 PM logoETFs with exposure to Lannett Co., Inc. : September 28, 2017 - October 2 at 12:30 PM logoCorporate News Blog - Lannett Gets FDA Approval for Oxycodone and Acetaminophen Tablets USP - October 2 at 12:30 PM logoLannett Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules USP, One Each For Full Prescription And OTC - October 2 at 12:30 PM logoSmall Caps Continue to Outperform on Tax Reform, Oil Marches Higher - ICYMI - - September 28 at 1:59 AM logoA Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Reports, Fed Speakers - Benzinga - September 27 at 10:26 AM logoLannett Receives FDA Approval For Oxycodone And Acetaminophen Tablets USP, 5 mg/325 mg And 10 mg/325 mg - September 27 at 10:26 AM logoLannett Receives Approval For Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg And 10 mg - PR Newswire (press release) - September 26 at 9:41 AM logoLannett (LCI) Says Class Action Lawsuit Dismissed - - - September 26 at 9:41 AM logoLannett Announces Dismissal Of Class Action Lawsuit - September 26 at 9:41 AM logoLannett Receives Approval For Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg And 10 mg - September 26 at 9:41 AM logoLannett (LCI) Initiates CEO Search; Arthur Bedrosian to Step Down Upon Naming of Successor - - September 25 at 8:56 AM logoLannett's Board Of Directors Initiates CEO Search - September 25 at 8:56 AM logoArthur Bedrosian, Lannett CEO, Prevails In Lawsuit With Internal Revenue Service - PR Newswire (press release) - September 24 at 7:06 PM logoArthur Bedrosian, Lannett CEO, Prevails In Lawsuit With Internal Revenue Service - September 22 at 11:36 AM logoLannett Company, Inc. (LCI) Receives Average Recommendation of "Hold" from Analysts - September 12 at 9:02 PM logoFDA approves Lannett's Esomeprazole Magnesium delayed-release capsules USP, 20 mg and 40 mg - September 6 at 9:28 PM logoLannett (LCI) Granted FDA Approval For Esomeprazole Magnesium Delayed-Release Capsules - September 6 at 9:28 PM logoWhat Is Lannett Company Inc’s (LCI) Share Price Doing? - September 6 at 9:28 PM logo Analysts Anticipate Lannett Co Inc (LCI) Will Post Quarterly Sales of $153.21 Million - September 6 at 7:42 AM logoLannett Scores FDA OK for Nexium Generic-Biotech Movers - - September 5 at 3:49 PM logoLannett Receives Approval For Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg And 40 mg - September 5 at 3:49 PM logoLannett Scores FDA OK for Nexium Generic-Biotech Movers - September 5 at 3:49 PM logoLannett receives FDA OK for generic Nexium product - September 5 at 3:49 PM logoETFs with exposure to Lannett Co., Inc. : September 2, 2017 - September 2 at 4:14 AM logoLannett Co., Inc. :LCI-US: Earnings Analysis: 2017 By the Numbers : August 30, 2017 - August 31 at 6:50 AM logoSanofi (SNY) and Lannett Co (LCI) Financial Contrast - August 30 at 6:18 PM logoOppenheimer Holdings Comments on Lannett Co Inc's Q1 2018 Earnings (LCI) - August 28 at 4:26 AM logoEquities Analysts Issue Forecasts for Lannett Co Inc's Q2 2018 Earnings (LCI) - August 25 at 10:36 AM logoEdited Transcript of LCI earnings conference call or presentation 23-Aug-17 8:30pm GMT - August 25 at 7:50 AM logoLannett Co's (LCI) "Market Perform" Rating Reaffirmed at BMO Capital Markets - August 24 at 8:52 PM logoLannett Co Inc (LCI) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc. - August 24 at 7:36 PM logoLannett's (LCI) CEO Arthur Bedrosian on Q4 2017 Results - Earnings Call Transcript - August 24 at 8:35 AM logoInvestor Network: Lannett Company, Inc. to Host Earnings Call - August 24 at 8:34 AM logoLannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018 - August 24 at 8:34 AM logoLannett posts 4Q profit - August 24 at 8:34 AM logoComparing Lannett Co (LCI) & SciClone Pharmaceuticals (SCLN) - August 23 at 10:22 PM



Lannett Co (LCI) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.